File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells

TitleEstrogen and antiestrogen regulation of cell cycle progression in breast cancer cells
Authors
Issue Date2003
Citation
Endocrine-Related Cancer, 2003, v. 10, n. 2, p. 179-186 How to Cite?
AbstractThe central involvement of estrogen in the development of the mammary gland and in the genesis of breast cancer has lent impetus to studies of the links between estrogen action and the cell cycle machinery. Recent studies of the estrogenic regulation of molecules with known roles in the control of G1/S phase progression have resulted in significant advances in understanding these links. Estrogens independently regulate the expression and function of c-Myc and cyclin D1 and the induction of either c-Myc or cyclin D1 is sufficient to recapitulate the effects of estrogen on cell cycle progression. These pathways converge at the activation of cyclin E-Cdk2 complexes. The active cyclin E-Cdk2 complexes are depleted of the cyclin dependent kinase (CDK) inhibitor p21WAF1/CIP1 because of estrogen-mediated inhibition of nascent p21WAF1/CIP1. Insulin and estrogen synergistically stimulate cell cycle progression, and the ability of estrogen to antagonize an insulin-induced increase in p21WAF1/CIP1 gene expression appears to underlie this effect. Antiestrogen treatment of MCF-7 cells leads to an acute decrease of c-Myc expression, a subsequent decline in cyclin D1, and ultimately arrest of cells in a state with features characteristic of quiescence. An antisense-mediated decrease in c-Myc expression results in decreased cyclin D1 expression and inhibition of DNA synthesis, mimicking the effects of antiestrogen treatment and emphasizing the importance of c-Myc as an estrogen/antiestrogen target. These data identify c-Myc, cyclin D1, p21WAF1/CIP1 and cyclin E-Cdk2 as central components of estrogen regulation of cell cycle progression and hence as potential downstream targets that contribute to the role of estrogen in oncogenesis.
Persistent Identifierhttp://hdl.handle.net/10722/326448
ISSN
2023 Impact Factor: 4.1
2023 SCImago Journal Rankings: 1.331
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorDoisneau-Sixou, S. F.-
dc.contributor.authorSergio, C. M.-
dc.contributor.authorCarroll, J. S.-
dc.contributor.authorHui, R.-
dc.contributor.authorMusgrove, E. A.-
dc.contributor.authorSutherland, R. L.-
dc.date.accessioned2023-03-10T02:19:21Z-
dc.date.available2023-03-10T02:19:21Z-
dc.date.issued2003-
dc.identifier.citationEndocrine-Related Cancer, 2003, v. 10, n. 2, p. 179-186-
dc.identifier.issn1351-0088-
dc.identifier.urihttp://hdl.handle.net/10722/326448-
dc.description.abstractThe central involvement of estrogen in the development of the mammary gland and in the genesis of breast cancer has lent impetus to studies of the links between estrogen action and the cell cycle machinery. Recent studies of the estrogenic regulation of molecules with known roles in the control of G1/S phase progression have resulted in significant advances in understanding these links. Estrogens independently regulate the expression and function of c-Myc and cyclin D1 and the induction of either c-Myc or cyclin D1 is sufficient to recapitulate the effects of estrogen on cell cycle progression. These pathways converge at the activation of cyclin E-Cdk2 complexes. The active cyclin E-Cdk2 complexes are depleted of the cyclin dependent kinase (CDK) inhibitor p21WAF1/CIP1 because of estrogen-mediated inhibition of nascent p21WAF1/CIP1. Insulin and estrogen synergistically stimulate cell cycle progression, and the ability of estrogen to antagonize an insulin-induced increase in p21WAF1/CIP1 gene expression appears to underlie this effect. Antiestrogen treatment of MCF-7 cells leads to an acute decrease of c-Myc expression, a subsequent decline in cyclin D1, and ultimately arrest of cells in a state with features characteristic of quiescence. An antisense-mediated decrease in c-Myc expression results in decreased cyclin D1 expression and inhibition of DNA synthesis, mimicking the effects of antiestrogen treatment and emphasizing the importance of c-Myc as an estrogen/antiestrogen target. These data identify c-Myc, cyclin D1, p21WAF1/CIP1 and cyclin E-Cdk2 as central components of estrogen regulation of cell cycle progression and hence as potential downstream targets that contribute to the role of estrogen in oncogenesis.-
dc.languageeng-
dc.relation.ispartofEndocrine-Related Cancer-
dc.titleEstrogen and antiestrogen regulation of cell cycle progression in breast cancer cells-
dc.typeConference_Paper-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1677/erc.0.0100179-
dc.identifier.pmid12790780-
dc.identifier.scopuseid_2-s2.0-0038613810-
dc.identifier.volume10-
dc.identifier.issue2-
dc.identifier.spage179-
dc.identifier.epage186-
dc.identifier.isiWOS:000184151400008-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats